Properties of a filamentous virus of the honey bee (Apis mellifera)

An ellipsoidal particle, measuring 450 x 150 nm, from honey bees comprises a nucleocapsid measuring 3000 x 40 nm, containing double-stranded DNA with a molecular weight of approximately 12 x 10(6), which is coiled within a membrane. The buoyant densities in CsCl of the whole particle, nucleocapsid, DNA and DNA with ethidium bromide are 1.28, 1.36, 1.71 and 1.61 g/ml, respectively. The particle contains about 12 proteins, with molecular weights ranging from 13,000 to 70,000, which are distributed approximately equally between the membrane and the nucleocapsid.     

Vestibular projections to the nuclei of the extraocular muscles Degeneration resulting from discrete partial lesions of the vestibular nuclei in the monkey

In 35 monkeys attempts were made to produce localized unilateral lesions in individual vestibular nuclei in order to study vestibular projections to nuclei of the extraocular muscles. Portions of the medial, superior and inferior vestibular nuclei were destroyed selectively; lesions in Deiters' nucleus involved small portions of either the superior or inferior vestibular nuclei. Fiber degeneration was studied by the Nauta-Gygax technic. Exclusively ascending fibers from the superior vestibular nucleus project to ipsilateral extraocular nuclei. Ascending fibers from the inferior vestibular arise only from rostral portions of the nucleus, are not numerous and pass to all extraocular nuclei. The medial vestibular nucleus projects ascending fibers via the MLF bilaterally, asymmetrically and differentially to all extraocular nuclei. Prominent projections pass to: (a) the contralateral trochlear nucleus, and (b) the contralateral intermediate cell column and the ipsilateral ventral nucleus of the oculomotor complex. Ascending fibers from Deiters' nucleus, arising only from ventral portions of the nucleus, project primarily to: (a) the contralateral abducens and trochlear nuclei, and (b) specific asymmetrical portions of the oculomotor complex. Ascending vestibular fibers from the medial and lateral vestibular nuclei appear capable of mediating all patterned eye movements resulting from stimulation of ampullary nerves from individual semicircular canals. Vestibular projections to nuclei of the extraocular muscles are most abundant to those nuclei innervating muscles whose primary functions concern horizontal and rotatory eye movements.     

Features associated with suicide attempts in recurrent major depression

Sixty-seven individuals with recurrent major depression and a history of suicide attempts are compared with 163 individuals with recurrent major depression and no history of suicide attempts. The groups are contrasted on demographic features, clinical course, severity of depression, co-morbidity, and acute symptom profiles. Patients with a history of attempts are distinguished from non-attempters by suicidal ideation, marital isolation, neurovegetative signs, feelings of failure, and co-morbid alcoholism or bipolar II disorder. Logistic regression analysis using a model which included a portion of the significant variables correctly classified 77% of the cases. These findings are discussed with reference to prediction of suicide attempts in individuals with major affective disorder.     

A monoclonal blocking EIA for herpes simplex virus type 2 antibody: validation for seroepidemiological studies in Africa

A competitive type-specific enzyme-linked immunosorbent assay (ELISA) for herpes simplex virus type 2 (HSV-2) antibody was developed using an infected cell antigen and a monoclonal antibody to glycoprotein G-2. This assay has been validated for use for epidemiological studies using a large panel of sera collected in rural Uganda and a panel of 143 sera characterised previously by Western blotting, the 'gold standard' for HSV type-specific serology. This evaluation was found to have a sensitivity of 96% and a specificity of 91% in comparison with Western blot on 143 sera from clinic patients. The ELISA had a sensitivity of 93% and a specificity of 91% in comparison with Western blot on 495 sera collected in Uganda. The assay showed good reproducibility and a low percentage of sera gave equivocal results, indicating its suitability for epidemiological studies.     

Epidemiologic modeling using a microcomputer spreadsheet package

Epidemiologic modeling has provided both researchers and students with a means of studying complex disease processes as well as making intervention recommendations to decision makers. To develop more than the most elementary model, however, it has become necessary to be well versed in a computer programming language. While this has deterred many modelers in the past, with microcomputers it is now possible to develop even complex models without significant investment of time spent in learning a computer language. In addition to being affordable, many microcomputers offer "canned" spreadsheet packages which are readily adapted for epidemiologic modeling. To demonstrate this, two models were developed and run using a microcomputer spreadsheet package: 1) the classic Reed-Frost model, and 2) a modified Reed-Frost model with two intermixing subpopulations.     

Response of the ENPP1-Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice

Inactivating mutations in human ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) may result in early-onset osteoporosis (EOOP) in haploinsufficiency and autosomal recessive hypophosphatemic rickets (ARHR2) in homozygous deficiency. ARHR2 patients are frequently treated with phosphate supplementation to ameliorate the rachitic phenotype, but elevating plasma phosphorus concentrations in ARHR2 patients may increase the risk of ectopic calcification without increasing bone mass. To assess the risks and efficacy of conventional ARHR2 therapy, we performed comprehensive evaluations of ARHR2 patients at two academic medical centers and compared their skeletal and renal phenotypes with ENPP1-deficient Enpp1^asj/asj mice on an acceleration diet containing high phosphate treated with recombinant murine Enpp1-Fc. ARHR2 patients treated with conventional therapy demonstrated improvements in rickets, but all adults and one adolescent analyzed continued to exhibit low bone mineral density (BMD). In addition, conventional therapy was associated with the development of medullary nephrocalcinosis in half of the treated patients. Similar to Enpp1^asj/asj mice on normal chow and to patients with mono- and biallelic ENPP1 mutations, 5-week-old Enpp1^asj/asj mice on the high-phosphate diet exhibited lower trabecular bone mass, reduced cortical bone mass, and greater bone fragility. Treating the Enpp1^asj/asj mice with recombinant Enpp1-Fc protein between weeks 2 and 5 normalized trabecular bone mass, normalized or improved bone biomechanical properties, and prevented the development of nephrocalcinosis and renal failure. The data suggest that conventional ARHR2 therapy does not address low BMD inherent in ENPP1 deficiency, and that ENPP1 enzyme replacement may be effective for correcting low bone mass in ARHR2 patients without increasing the risk of nephrocalcinosis. © 2021 American Society for Bone and Mineral Research (ASBMR).     

Burosumab for the Treatment of Tumor-Induced Osteomalacia

Tumor-induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FGF23) and is characterized by impaired phosphate metabolism, skeletal health, and quality of life. UX023T-CL201 is an ongoing, open-label, phase 2 study investigating the safety and efficacy of burosumab, a fully human monoclonal antibody that inhibits FGF23, in adults with TIO or cutaneous skeletal hypophosphatemia syndrome (CSHS). Key endpoints were changes in serum phosphorus and osteomalacia assessed by transiliac bone biopsies at week 48. This report focuses on 14 patients with TIO, excluding two diagnosed with X-linked hypophosphatemia post-enrollment and one with CSHS. Serum phosphorus increased from baseline (0.52 mmol/L) and was maintained after dose titration from week 22 (0.91 mmol/L) to week 144 (0.82 mmol/L, p < 0.0001). Most measures of osteomalacia were improved at week 48: osteoid volume/bone, osteoid thickness, and mineralization lag time decreased; osteoid surface/bone surface showed no change. Of 249 fractures/pseudofractures detected across 14 patients at baseline, 33% were fully healed and 13% were partially healed at week 144. Patients reported a reduction in pain and fatigue and an increase in physical health. Two patients discontinued: one to treat an adverse event (AE) of neoplasm progression and one failed to meet dosing criteria (receiving minimal burosumab). Sixteen serious AEs occurred in seven patients, and there was one death; all serious AEs were considered unrelated to treatment. Nine patients had 16 treatment-related AEs; all were mild to moderate in severity. In adults with TIO, burosumab exhibited an acceptable safety profile and was associated with improvements in phosphate metabolism and osteomalacia. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research..